Inhibikase Therapeutics (IKT) Research & Development (2020 - 2024)
Historic Research & Development for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to $7.2 million.
- Inhibikase Therapeutics' Research & Development rose 13954.76% to $7.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $17.2 million, marking a year-over-year increase of 2637.76%. This contributed to the annual value of $17.2 million for FY2024, which is 2637.76% up from last year.
- As of Q4 2024, Inhibikase Therapeutics' Research & Development stood at $7.2 million, which was up 13954.76% from $4.2 million recorded in Q3 2024.
- In the past 5 years, Inhibikase Therapeutics' Research & Development registered a high of $7.2 million during Q4 2024, and its lowest value of $120569.0 during Q3 2020.
- In the last 5 years, Inhibikase Therapeutics' Research & Development had a median value of $3.0 million in 2022 and averaged $2.8 million.
- In the last 5 years, Inhibikase Therapeutics' Research & Development skyrocketed by 251638.81% in 2021 and then crashed by 3218.62% in 2024.
- Over the past 5 years, Inhibikase Therapeutics' Research & Development (Quarter) stood at $226944.0 in 2020, then soared by 1393.87% to $3.4 million in 2021, then decreased by 9.91% to $3.1 million in 2022, then decreased by 1.68% to $3.0 million in 2023, then soared by 139.55% to $7.2 million in 2024.
- Its Research & Development stands at $7.2 million for Q4 2024, versus $4.2 million for Q3 2024 and $3.1 million for Q2 2024.